105 related articles for article (PubMed ID: 2947734)
1. Clinical evaluation of the simultaneous blockade of the dopamine D-2, histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: results of a controlled trial.
Martin-Jimenez M; Diaz-Rubio E
Cancer Chemother Pharmacol; 1986; 18(2):168-71. PubMed ID: 2947734
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer.
Martin-Jimenez M; Diaz-Rubio E; Gonzalez Larriba JL; Sangro B
Eur J Gynaecol Oncol; 1987; 8(2):98-102. PubMed ID: 3552683
[TBL] [Abstract][Full Text] [Related]
3. Results of two controlled studies on antiemetic combination against vomiting induced by 5-fluorouracil.
Martin-Jimenez M; Diaz-Rubio E; Sangro B
Tumori; 1987 Oct; 73(5):499-504. PubMed ID: 3318052
[TBL] [Abstract][Full Text] [Related]
4. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.
Martin M; Diaz-Rubio E; Casado A; Dominguez S; Sastre J
Eur J Cancer; 1992; 28(2-3):430-2. PubMed ID: 1591058
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
6. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
Diaz-Rubio E; Martin M; Rosell R; Valerdi JJ; Gonzalez-Larriba JL; Barriga JJ
Acta Oncol; 1991; 30(3):339-42. PubMed ID: 2036244
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
[TBL] [Abstract][Full Text] [Related]
8. Antiemetic combination for cisplatin-induced emesis. Results from a controlled study.
Martín Jiménez M; Diaz-Rubio E
Bull Cancer; 1986; 73(3):294-8. PubMed ID: 3756365
[TBL] [Abstract][Full Text] [Related]
9. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
10. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions.
Peroutka SJ; Snyder SH
Lancet; 1982 Mar; 1(8273):658-9. PubMed ID: 6121969
[No Abstract] [Full Text] [Related]
11. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
[TBL] [Abstract][Full Text] [Related]
12. Optimal control of cyclophosphamide-induced emesis.
Stewart A
Oncology; 1996 Jun; 53 Suppl 1():32-8. PubMed ID: 8692548
[TBL] [Abstract][Full Text] [Related]
13. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
17. Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study.
Mellink WA; Blijham GH; van Deyk WA
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1147-50. PubMed ID: 6383839
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M
J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030
[TBL] [Abstract][Full Text] [Related]
19. Emesis: antiemetic effect of cyclophosphamide at central receptors of multitransmitter system in the cat.
Bosnjak S; Beleslin DB
Pharmacol Res; 2002 Nov; 46(5):425-34. PubMed ID: 12419647
[TBL] [Abstract][Full Text] [Related]
20. [Antiemetic treatments associated with antineoplastic chemotherapy].
Tres Sánchez A; Sáez Martínez MJ; Mayordomo Cámara JJ; Guillén Lloveria G; Sáenz Cusi A
An Med Interna; 1990 May; 7(5):229-32. PubMed ID: 2102716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
